SPRB
NASDAQSpruce Biosciences Inc.
Price$61.49+10.59 (+20.81%)
2026-05-222026-08-26
News · 26 weeks58+25%
2026-03-012026-08-23
Mix2490d
- Other12(50%)
- Leadership4(17%)
- Insider3(13%)
- SEC Filings3(13%)
- Analyst2(8%)
Latest news
25 items- PRSpruce Biosciences Announces Launch of MPS3BStudy.comWebsite Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory Study TA-ERT EAP and TrAnsform Confirmatory Study Both Expected to Initiate in the Fourth Quarter of 2026 Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the launch of MPS3BStudy.com, a dedicated online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB). The website enables families and caregivers to learn abo
- PRSpruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026FDA Found Spruce's Chemistry, Manufacturing and Controls (CMC) Comparability Strategies Reasonable to Support the BLA Following Technology Transfer to Leading Global Biologics Manufacturer Spruce and FDA Aligned on the Overall Content and Format of the Planned BLA, Including Structure of the Integrated Efficacy and Safety Summaries Spruce Continues to Advance Its Planned Biologics License Application (BLA) on the Accelerated Approval Pathway Based on Reduction of Cerebrospinal Fluid Heparan Sulfate Non-Reducing Ends (CSF HS-NRE) Spruce Biosciences, Inc. (NASDAQ:SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurol
- SECSEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECSEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECSEC Form 10-Q filed by Spruce Biosciences Inc.10-Q - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- SECSpruce Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- PRSpruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesBiologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform Confirmatory Study Required for Potential FDA Accelerated Approval of TA-ERT Expected to Initiate in the Fourth Quarter of 2026 Strengthened Leadership Team with the Appointments of Adrian Quartel, M.D., FFPM, as Chief Medical Officer and Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the second quarter
- PRCure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce BiosciencesInvestment Broadens Patient Access to Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B in the TA-ERT Expanded Access Program (EAP) TA-ERT EAP Expected to Initiate in the Fourth Quarter of 2026 Spruce Biosciences, Inc. (NASDAQ:SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Cure Sanfilippo Foundation and the National MPS Society have agreed to make a combined $5.5 million strategic investment in Spruce. The proceeds will be used to partially fund TA-ERT EAP, helping to broaden patient access to investigational TA-
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Spruce Biosciences Inc.SCHEDULE 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- PRSpruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical DevelopmentDr. Cohen Pfeffer Brings More Than a Decade of Clinical Development Leadership, Including Deep Experience with Enzyme Replacement Therapies for Rare Pediatric Neurodegenerative DisordersSpruce Biosciences, Inc. ("Spruce Biosciences" or "Spruce") (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development, effective today. Dr. Cohen Pfeffer brings more than a decade of biopharmaceutical industry experience spanning clinical development, product portfolio development and medica
- INSIDERSEC Form 4 filed by Chief Medical Officer Quartel Adrian W4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- INSIDERSEC Form 3 filed by new insider Quartel Adrian W3 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECSpruce Biosciences Inc. filed SEC Form 8-K: Leadership Update8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- PRSpruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical OfficerAccomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic DisordersSpruce Biosciences, Inc. ("Spruce Biosciences" or "Spruce") (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior roles spanning c
- ANALYSTB. Riley Securities initiated coverage on Spruce Biosciences with a new price targetB. Riley Securities initiated coverage of Spruce Biosciences with a rating of Buy and set a new price target of $160.00
- INSIDERCHIEF EXECUTIVE OFFICER Szwarcberg Javier B. was granted 266 shares, increasing direct ownership by 1% to 19,270 units (SEC Form 4)4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- PRSpruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare SummitSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.The B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.Participation in the summit is by invitation only. Investors interested in scheduling an in-person
- PRSpruce Biosciences Joins the Russell 3000® IndexInclusion Reflects Spruce’s Momentum as the Company Advances Toward a Planned Biologics License Application (BLA) Submission and Potential Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has been added as a member of the Russell 3000® Index, effective with the opening of U.S. equity markets today, in connection with the 2026 Russell U.S. Indexes Reconstitution. The Russell 3000® Index measures the
- PRSpruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical AffairsDr. Jurecka Brings Deep Enzyme Replacement Therapy and Rare Disease Experience to Lead Medical Affairs and Scientific Engagement Ahead of Potential U.S. FDA Approval of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Agnieszka "AJ" Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs. "We are delighted to welcome AJ to the Spruce executive team. She is a rare combination of practic
- ANALYSTGuggenheim initiated coverage on Spruce Biosciences with a new price targetGuggenheim initiated coverage of Spruce Biosciences with a rating of Buy and set a new price target of $123.00
- PRSpruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate ControllerAppointments Further Strengthen Spruce's Commercial and Financial Capabilities as the Company Approaches a Potential U.S. FDA Approval and Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointments of Eric Jordan as Vice President, Marketing and Tina Gullotta, CPA, as Vice President, Finance and Corporate Controller."We are delighted to welcome both Eric and Tina, two accomplished leaders
- PRSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS SymposiumData Highlight TA-ERT's Potential as the First Disease-Modifying Treatment Option for MPS IIIB, a Fatal Condition With No Approved Therapies Treatment With Weekly TA-ERT Demonstrated Rapid and Durable Normalization of CSF Heparan Sulfate Non-Reducing End (CSF HS-NRE), a Surrogate Endpoint Reasonably Likely to Predict Clinical Benefit TA-ERT Stabilized and Preserved Cognitive and Non-Cognitive Outcomes, Including Communication and Motor Skills, Over a Six-Year Period Relative to Natural History Patients Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unme
- PRSpruce Biosciences Announces Data Presentation at the 18th International MPS SymposiumNicole Muschol, M.D. to Present Long-Term Data on Tralesinidase Alfa (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB) will be presented at the 18th International MPS & Related Lysosomal Diseases Symposium, taking place June 4-7, 2026 in Florence, Italy. International MPS Symposium Presentation Details Title: Lo
- PRSpruce Biosciences to Participate in Upcoming Conferences in JuneSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that members of the management team will present and participate in one-on-one meetings at upcoming conferences taking place in June. Jefferies Global Healthcare Conference Date and Time: June 4, 2026, at 11:05 a.m. ET Format: Presentation and 1x1 meetings Location: New York Interested parties can access the live webcast for the Jefferies Global Healthcare Conference on the events section of the Company's website. An archived copy of the webcast will be available for appr
SPRB FAQ
7 questionsWhat does Spruce Biosciences Inc. do?
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH...Where does SPRB stock trade?
Spruce Biosciences Inc. (SPRB) is listed on NASDAQ.What sector and industry is SPRB in?
Spruce Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Spruce Biosciences Inc. go public?
Spruce Biosciences Inc. (SPRB) completed its IPO in 2020.What are analysts saying about SPRB?
Spruce Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy on 2026-07-13.What companies are similar to SPRB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SPRB side-by-side with any of them on Quantisnow.How can I track SPRB on Quantisnow?
Quantisnow aggregates Spruce Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SPRB to receive live email and push alerts on every new disclosure.